Trial reportOphthalmology2015
Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.
Trial report in Ophthalmology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Detection of intracranial hypertension in children using optical coherence tomography: a systematic review.BMJ open · 2021Pooled it
- Automated Retinal Vascular Analysis Reveals Response to Acetazolamide in Idiopathic Intracranial Hypertension.Translational vision science & technology · 2025Trial
- Inflammation and patient satisfaction in micropulse versus continuous wave transscleral cyclophotocoagulation.The British journal of ophthalmology · 2025Trial
- The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension.American journal of ophthalmology · 2018Trial
- Peripapillary Retinal Pigment Epithelium Layer Shape Changes From Acetazolamide Treatment in the Idiopathic Intracranial Hypertension Treatment Trial.Investigative ophthalmology & visual science · 2017Trial
- The Effect of Treatment of Idiopathic Intracranial Hypertension on Prevalence of Retinal and Choroidal Folds.American journal of ophthalmology · 2017Trial
- A Spectral-Domain-OCT-Guided One-Year Follow-Up of Newly Diagnosed Pediatric Idiopathic Intracranial Hypertension Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Peripapillary Choroidal Vascularity Index for Differentiating Papilledema from Pseudopapilledema: A Deep Learning-Based Approach.Ophthalmology science · 2026Article
- Ophthalmologic assessment and intracranial pressure in children: diagnostic methods, clinical correlations, and future directions.Frontiers in pediatrics · 2026Review
- Neuroretinal structure changes in infantile nephropathic cystinosis.Orphanet journal of rare diseases · 2025Article
- Identifying biomarkers for papilledema and pseudopapilledema.Scientific reports · 2025Article
- Imaging the optic nerve with optical coherence tomography.Eye (London, England) · 2024Review
- Visualization of Optic Nerve Structural Patterns in Papilledema Using Deep Learning Variational Autoencoders.Translational vision science & technology · 2024Article
- Which OCT Measure of the Optic Nerve Head Improves Fastest? Towards Optimizing Early Detection of Resolving Papilledema in Children.Translational vision science & technology · 2024Article
- Classifying and quantifying changes in papilloedema using machine learning.BMJ neurology open · 2024Article
- Neuro-ophthalmic features of patients with spontaneous cerebrospinal fluid leaks.Medical hypothesis, discovery & innovation ophthalmology journal · 2023Article
- Optical coherence tomography features and correlation of functional and structural parameters in patients of idiopathic intracranial hypertension.Indian journal of ophthalmology · 2022Observational
- An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management.Journal of neurology · 2021Review
- Unilateral Optic Nerve Sheath Fenestration in Idiopathic Intracranial Hypertension: A 6-Month Follow-Up Study on Visual Outcome and Prognostic Markers.Life (Basel, Switzerland) · 2021Article
- Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammation markers in patients with papilledema due to idiopathic intracranial hypertension.Indian journal of ophthalmology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
purposeTo assess treatment efficacy using spectral-domain (SD) optical coherence tomography (OCT) measurements of papilledema in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), which evaluated the effects of acetazolamide and weight management and of placebo and weight management in eyes with mild visual loss.
designRandomized double-masked control clinical trial of acetazolamide plus weight management compared with placebo plus weight management in subjects with mild visual field loss and previously untreated idiopathic intracranial hypertension (IIH).
participantsEighty-nine (43 acetazolamide treated, 46 placebo treated) of 165 subjects meeting IIHTT entry criteria.
methodsSubjects underwent perimetry, papilledema grading (Frisén method), high- and low-contrast visual acuity, and SD OCT imaging at study entry and 3 and 6 months. Study eye results (worse perimetric mean deviation [PMD]) were used for most analyses.
main outcome measuresRetinal nerve fiber layer (RNFL) thickness, total retinal thickness (TRT), optic nerve (ONH) volume, and retinal ganglion cell layer (RGCL) measurements derived using 3-dimensional segmentation.
resultsStudy entry OCT values were similar in both treatment groups. At 6 months, the acetazolamide group had greater reduction than the placebo group for RNFL thickness (175 μm vs. 89 μm; P = 0.001), TRT (220 μm vs. 113 μm; P = 0.001), and ONH volume (4.9 mm(3) vs. 2.1 mm(3); P = 0.001). The RNFL thickness (P = 0.01), TRT (P = 0.003), and ONH volume (P = 0.002) measurements also showed smaller increases in subjects who lost 6% or more of study entry weight. The acetazolamide (3.6 μm) and placebo (2.1 μm) groups showed minor RGCL thinning (P = 0.06). The RNFL thickness, TRT, and ONH volume measurements showed moderate correlations (r = 0.48-0.59; P ≤ 0.0001) with Frisén grade. The 14 eyes with RGCL thickness less than the fifth percentile of controls had worse PMD (P = 0.001) than study eyes with RGCL in the fifth percentile or more.
conclusionsIn IIH, acetazolamide and weight loss effectively improve RNFL thickness, TRT, and ONH volume swelling measurements resulting from papilledema. In contrast to the strong correlation at baseline, OCT measures at 6 months show only moderate correlations with papilledema grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.